697 related articles for article (PubMed ID: 7722448)
1. Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease.
Chuenkova M; Pereira ME
J Exp Med; 1995 May; 181(5):1693-703. PubMed ID: 7722448
[TBL] [Abstract][Full Text] [Related]
2. Invasive phenotype of Trypanosoma cruzi restricted to a population expressing trans-sialidase.
Pereira ME; Zhang K; Gong Y; Herrera EM; Ming M
Infect Immun; 1996 Sep; 64(9):3884-92. PubMed ID: 8751943
[TBL] [Abstract][Full Text] [Related]
3. In vivo infection by Trypanosoma cruzi: the conserved FLY domain of the gp85/trans-sialidase family potentiates host infection.
Tonelli RR; Torrecilhas AC; Jacysyn JF; Juliano MA; Colli W; Alves MJ
Parasitology; 2011 Apr; 138(4):481-92. PubMed ID: 21040619
[TBL] [Abstract][Full Text] [Related]
4. The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contents.
Tribulatti MV; Mucci J; Van Rooijen N; Leguizamón MS; Campetella O
Infect Immun; 2005 Jan; 73(1):201-7. PubMed ID: 15618155
[TBL] [Abstract][Full Text] [Related]
5. The trans-sialidase, the major Trypanosoma cruzi virulence factor: Three decades of studies.
Freire-de-Lima L; Fonseca LM; Oeltmann T; Mendonça-Previato L; Previato JO
Glycobiology; 2015 Nov; 25(11):1142-9. PubMed ID: 26224786
[TBL] [Abstract][Full Text] [Related]
6. Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate.
Fontanella GH; De Vusser K; Laroy W; Daurelio L; Nocito AL; Revelli S; Contreras R
Vaccine; 2008 May; 26(19):2322-34. PubMed ID: 18403070
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Applicability of Neutralizing Antibodies to Trypanosoma cruzi Trans-sialidase.
Leguizamón MS
Methods Mol Biol; 2019; 1955():239-246. PubMed ID: 30868532
[TBL] [Abstract][Full Text] [Related]
8. Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice.
Costa F; Franchin G; Pereira-Chioccola VL; Ribeirão M; Schenkman S; Rodrigues MM
Vaccine; 1998 May; 16(8):768-74. PubMed ID: 9627933
[TBL] [Abstract][Full Text] [Related]
9. Trypanosoma cruzi trans-sialidase in complex with a neutralizing antibody: structure/function studies towards the rational design of inhibitors.
Buschiazzo A; Muiá R; Larrieux N; Pitcovsky T; Mucci J; Campetella O
PLoS Pathog; 2012 Jan; 8(1):e1002474. PubMed ID: 22241998
[TBL] [Abstract][Full Text] [Related]
10. Immune system pathogenesis is prevented by the neutralization of the systemic trans-sialidase from Trypanosoma cruzi during severe infections.
Risso MG; Pitcovsky TA; Caccuri RL; Campetella O; Leguizamón MS
Parasitology; 2007 Apr; 134(Pt 4):503-10. PubMed ID: 17166319
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease.
Bontempi IA; Vicco MH; Cabrera G; Villar SR; González FB; Roggero EA; Ameloot P; Callewaert N; Pérez AR; Marcipar IS
Vaccine; 2015 Mar; 33(10):1274-83. PubMed ID: 25625671
[TBL] [Abstract][Full Text] [Related]
12. Trypanosoma cruzi-infected individuals demonstrate varied antibody responses to a panel of trans-sialidase proteins encoded by SA85-1 genes.
Duthie MS; Cetron MS; Van Voorhis WC; Kahn SJ
Acta Trop; 2005 Mar; 93(3):317-29. PubMed ID: 15725381
[TBL] [Abstract][Full Text] [Related]
13. Identification of Trypanosoma cruzi trans-sialidase family members as targets of protective CD8+ TC1 responses.
Wizel B; Nunes M; Tarleton RL
J Immunol; 1997 Dec; 159(12):6120-30. PubMed ID: 9550413
[TBL] [Abstract][Full Text] [Related]
14. Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.
Pereira-Chioccola VL; Fragata-Filho AA; Levy AM; Rodrigues MM; Schenkman S
Clin Diagn Lab Immunol; 2003 Sep; 10(5):826-30. PubMed ID: 12965912
[TBL] [Abstract][Full Text] [Related]
15. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.
Hoft DF; Eickhoff CS; Giddings OK; Vasconcelos JR; Rodrigues MM
J Immunol; 2007 Nov; 179(10):6889-900. PubMed ID: 17982080
[TBL] [Abstract][Full Text] [Related]
16. Antibodies inhibiting Trypanosoma cruzi trans-sialidase activity in sera from human infections.
Leguizamón MS; Campetella O; Russomando G; Almiron M; Guillen I; Ganzález Cappa SM; Frasch AC
J Infect Dis; 1994 Dec; 170(6):1570-4. PubMed ID: 7995998
[TBL] [Abstract][Full Text] [Related]
17. Trans-sialidase, SAPA amino acid repeats and the relationship between Trypanosoma cruzi and the mammalian host.
Frasch AC
Parasitology; 1994; 108 Suppl():S37-44. PubMed ID: 8084653
[TBL] [Abstract][Full Text] [Related]
18. Virulence in Trypanosoma cruzi infection correlates with the expression of a distinct family of sialidase superfamily genes.
Weston D; Patel B; Van Voorhis WC
Mol Biochem Parasitol; 1999 Jan; 98(1):105-16. PubMed ID: 10029313
[TBL] [Abstract][Full Text] [Related]
19. Thymocyte depletion in Trypanosoma cruzi infection is mediated by trans-sialidase-induced apoptosis on nurse cells complex.
Mucci J; Hidalgo A; Mocetti E; Argibay PF; Leguizamon MS; Campetella O
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3896-901. PubMed ID: 11891302
[TBL] [Abstract][Full Text] [Related]
20. Sera from chronic Chagasic patients and rodents infected with Trypanosoma cruzi inhibit trans-sialidase by recognizing its amino-terminal and catalytic domain.
Pereira-Chioccola VL; Schenkman S; Kloetzel JK
Infect Immun; 1994 Jul; 62(7):2973-8. PubMed ID: 8005683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
